Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and β-methyldigoxin in rats

Journal of Pharmaceutical Sciences

Volumn 92, Issue 7, 2003, Pages 1455-1463

  Funakoshi, Sachiyo ^a,b   Murakami, Teruo ^a   Yumoto, Ryoko ^a   Kiribayashi, Yoshie ^b   Takano, Mikihisa ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Chugoku Rousai Hospital   (Japan)

Author keywords

Digoxin; Drug interaction; P glycoprotein; Pharmacokinetics; methyldigoxin

Indexed keywords

CYCLOSPORIN A; DIGOXIN; GLYCOPROTEIN P; METILDIGOXIN; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CROSS REACTIVITY; DRUG TRANSPORT; INDIVIDUALIZATION; LIPOPHILICITY; MALE; NONHUMAN; PLASMA CLEARANCE; RAT; SMALL INTESTINE ABSORPTION; URINARY EXCRETION;

EID: 0038421230     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10416     Document Type: Article

References (45)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
2. Holash JA, Stewart PA. 1993. The relationship of astrocyte-like cells to the vessels that contribute to the blood - ocular barriers. Brain Res 629:218-224.
3. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. 1993. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with inhibitors. J Biol Chem 268: 14991-14997.
4. Lee JS, Pauli K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE. 1994. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46:627-638.
5. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D. 1994. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528-1530.
6. Schuetz EG, Beck WT, Schuetz JD. 1996. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
7. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
8. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. 2000. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 68:98-103.
9. Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. 2001. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 69:308-316.
10. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer-chemotherapy. Mol Carcinog 13:129-134.
11. Huang ZH, Murakami T, Okochi A, Yumoto R, Nagai J, Takano M. 2000. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol 406:453-460.
12. Huang ZH, Murakami T, Okochi A, Yumoto R, Nagai J, Takano M. 2001. Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure. J Pharm Pharmacol 53:873-881.
13. Murakami T, Yumoto R, Nagai J, Takano M. 2002. Factors affecting the expression and function of P-glycoprotein in rats: Drug treatments and diseased states. Pharmazie 57:102-107.
14. Das G. 1989. Beta-methyl digoxin: A better absorbable digoxin. Int J Clin Pharmacol Ther Toxicol 27:521-525.
15. Kuhlmann J, Rietbrock N, Schnieders B. 1979. Tissue distribution and elimination of digoxin and methyldigoxin after single and multiple doses in dogs. J Cardiovasc Pharmacol 1:219-234.
16. Davis TD, Vanderveen RL, Nienhuis M. 1983. Digoxin. In: Mungall DR, editor. Applied clinical pharmacokinetics. New York: Raven Press. pp 79-102.
17. Rodin SM, Johnson BF. 1988. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 15:227-244.
18. Nolan PE Jr, Raehl CL, Zarembski DG. 1996. Congestive heart failure. In: Herfindal ET, Gourley DR, editors. Textbook of therapeutics drug and disease management, 6th ed. Cardiovascular disorders, section 10. Baltimore: Williams & Wilkins, pp 729-761.
19. De Lannoy IA, Koren G, Klein J, Charuk J, Silverman M. 1992. Cyclosporin and quinidine inhibition of renal digoxin excretion: Evidence for luminal secretion of digoxin. Am J Physiol 26: F613-F622.
20. De Lannoy IA, Silverman M. 1992. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189:551-557.
21. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
22. Cavet ME, West M, Simmons NL. 1996. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118:1389-1396.
23. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH. 1996. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr la P-glycoprotein. Br J Pharmacol 119:1038-1044.
24. Pauli-Magnus C, Mürdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF. 2001. P-glycoprotein-mediated transport of digitoxin, α-methyldigoxin and β-acetyldigoxin. Naunyn Schmiedeberg's Arch Pharmacol 363:337-343.
25. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. 1999. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557.
26. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. 1999. P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacol Res 40:301-306.
27. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
28. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. 2002. Three-dimensional quantitative structure activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-973.
29. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. 2002. Application of three-dimensional quantitative structure - activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
30. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. 2001. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584-591.
31. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K. 2002. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci 70:1491-1500.
32. De Cesaris R, Balestrazzi M, Chiarappa R, Ranieri G. 1983. Interaction between verapamil and beta-methyldigoxin. Study by 86Rubidium uptake in erythrocytes. Int J Clin Pharmacol Res 3:107-109.
33. Enomoto N, Yokota M, Sotobata I, Goto J, Ando K, Sobue I. 1988. Effects of calcium channel blockers on the pharmacokinetics of oral beta-methyldigoxin. Nippon Naika Gakkai Zasshi 77:781-787.
34. Yumoto R, Murakami T, Nakamoto R, Hasegawa R, Nagai J, Takano M. 1999. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149-155.
35. Cohnen E, Flasch H, Heinz N, Hempelmann FW. 1978. Verteilungskoeffizienten unt Rm-Werte von Cardenoliden. Drug Res 28:2179-2182.
36. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A. 1999. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci 88:1281-1287.
37. Tsuji A, Tamai I. 1996. Carrier-mediated intestinal transport of drugs. Pharm Res 13:963-977.
38. Arimori K, Nakano M. 1998. Drug exsorption from blood into the gastrointestinal tract. Pharm Res 15:371-376.
39. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. 1999. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release 62:25-31.
40. Trezise AE, Romano PR, Gill DR, Hyde SC, Sepulveda FV, Buchwald M, Higgins CF. 1992. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J 11:4291-4303.
41. Sababi M, Borga O, Hultkvist-Bengtsson U. 2001. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 14:21-27.
42. Hinderling PH, Garrett ER, Wester RC. 1977. Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability. J Pharm Sci 66:314-325.
43. Rietbrock N, Guggenmos J, Kuhlmann J, Hess U. 1976. Bioavailability and pharmacokinetics of beta-methyldigoxin after multiple oral and intravenous doses. Eur J Clin Pharmacol 9:373-379.
44. Song S, Suzuki H, Kawai R, Sugiyama Y. 1999. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27:689-694.
45. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T, Hori R. 1993. Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 266:1614-1619.